180 Life Sciences (NASDAQ:ATNF) Earns “Sell (E+)” Rating from Weiss Ratings

180 Life Sciences (NASDAQ:ATNF)‘s stock had its “sell (e+)” rating restated by equities researchers at Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.

180 Life Sciences Stock Down 5.0 %

NASDAQ ATNF opened at $1.33 on Friday. 180 Life Sciences has a 52 week low of $1.16 and a 52 week high of $17.75. The company has a fifty day moving average of $1.86 and a two-hundred day moving average of $2.19.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.